Last updated: 07/17/2019 06:00:36
A Pivotal Subjective Sleep Study of a Nasal Dilator (Breathe Right Tan)
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Pivotal Subjective Sleep Study of a Nasal Dilator
Trial description: This randomized, double-blind, parallel group, placebo-controlled study assessed the effects of a novel nasal dilator strip in consumers with chronic nocturnal nasal congestion who have trouble with their sleep. Participants who met the entrance criteria were suffering from nasal congestion every night or almost every night, reported trouble with their sleep and had baseline nasal openness scores at bedtime during the qualification phase of ≤ 70 on a 100-point Visual Analogue Scale (VAS) on at least four of seven qualification nights were randomized to one of two treatments for use at home. Participants returned to the study site after 7 and 14 days of nightly nasal strip use where they self-administered the validated subjective questionnaire “the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)".
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Change from baseline in mean total score of the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) for each domain (sleep, sleep time, symptoms on waking in the morning, and practical problems) at Day 7
Timeframe: At Baseline and Day 7
Change from baseline in mean total score of the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) for each domain (sleep, sleep time, symptoms on waking in the morning, and practical problems) at Day 14
Timeframe: At Baseline and Day 14
Change from baseline in mean score of four questions on the domain Symptoms on Waking in the Morning in Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) at Day 7
Timeframe: At Baseline and Day 7
Change from baseline in mean score of four questions on the domain Symptoms on Waking in the Morning in Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) at Day 14
Timeframe: At Baseline and Day 14
Number of participants showing improvement for each domain (sleep, sleep time, symptoms on waking in the morning, and practical problems) of Nocturnal Rhino Conjunctivitis Quality of Life Questionnaire (NRQLQ) at Day 7
Timeframe: At Day 7
Number of participants showing improvement for each domain (sleep, sleep time, symptoms on waking in the morning, and practical problems) of Nocturnal Rhino Conjunctivitis Quality of Life Questionnaire (NRQLQ) at Day 14
Timeframe: At Day 14
Secondary outcomes:
Change from baseline in mean score in response to daily diary Visual Analogue Scale (VAS) questions (Q1 and Q3) at Day 1, 3, 7 and 14 in night
Timeframe: At Baseline, Day 1, 3, 7 and 14
Change from baseline in mean score in response to daily diary Visual analogue scale (VAS) questions (Q1 and Q3) at Day 1, 3, 7 and 14 in morning
Timeframe: At Baseline, Day 1, 3, 7 and 14
Change from baseline in mean score in response to daily diary Visual Analogue Scale (VAS) questions (Q2) at Day 1, 3, 7 and 14 in night
Timeframe: At Baseline, Day 1, 3, 7 and 14
Change from baseline in mean score in response to daily diary Visual Analogue Scale (VAS) questions (Q2) at Day 1, 3, 7 and 14 in morning
Timeframe: At Baseline, Day 1, 3, 7 and 14
Number of participants showing improvement on daily dairy questions at Day 1, 3, 7 and 14 at night
Timeframe: At Baseline, Day 1, 3, 7 and 14
Interventions:
Enrollment:
140
Primary completion date:
2011-14-01
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Congestion, Nasal
Product
Not applicable
Collaborators
Not applicable
Study date(s)
October 2010 to January 2011
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Consent: Demonstrated understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- Compliance: Understands and is willing, able and likely to comply with all study procedures and restrictions.
- Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds), allergy or atopic reaction to adhesive bandages or latex.
- Participant has current or a history of skin cancer, chronic skin condition, or eczema on the face or nose.
Inclusion and exclusion criteria
Inclusion criteria:
- Consent: Demonstrated understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- Compliance: Understands and is willing, able and likely to comply with all study procedures and restrictions.
- General Health: Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination.
- Contraception: Females of childbearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception.
- Leptorrhine Nose: Has a leptorrhine nose as defined in Appendix I to this protocol (nasal tip protrusion index of 45 or greater)
- Chronic Nasal Congestion: Complains of chronic nocturnal nasal congestion for at least the last year. When experiencing nasal congestion, complains always or almost always every night.
- Sleep: Reports trouble with sleep.
- VAS Nasal Openness Qualifying Question: Has baseline nasal openness scores at bedtime during the one-week baseline qualification phase of ≤ 70 on a 100-point VAS where 0=extremely blocked and 100=extremely open on at least four of seven nights.
Exclusion criteria:
- Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds), allergy or atopic reaction to adhesive bandages or latex.
- Participant has current or a history of skin cancer, chronic skin condition, or eczema on the face or nose.
- Participant has visible open sores, sunburn, irritation on the face or nose immediately prior to randomization.
- Participant has been diagnosed with sleep apnea in a sleep laboratory.
- Participant has had a diagnosis of another major sleep disorder (i.e. primary insomnia, i.e. regularly sleeping less than six hours per night, sleep insufficiency, i.e. sleeping >two hours more on non-work days as compared to work days, narcolepsy, restless leg syndrome, or periodic limb movement disorder).
- Participant has a non-typical sleep schedule (e.g. shift-work).
- Participant plans travel involving time-zone changes during the study period.
- Regular/habitual consumption of more than five cups or glasses per day of xanthine-containing beverages (i.e. tea, coffee, cola).
- Participant currently uses any product or medication that has an effect on nasal congestion or sleep. Participant must have discontinued use of the following products according to the timings specified below: a) Prior to initiation of the baseline qualification phase: i. Use of any substance with psychotropic effects or properties known to affect sleep/wake, including but not limited to: neuroleptics, morphine/opioid derivatives, sedative antihistamines, stimulants, antidepressants, clonidine, barbiturates, anxiolytics, thalidomide, hypnotics and sedatives. Use of over-the-counter (OTC) sleep promoting agents including diphenhydramine, doxylamine, tryptophan, valerian root, kava kava, melatonin, St John’s Wort and Alluna. Use of OTC alertness aids including caffeine and guarana. ii. Lubricating sprays/rinses/throat strips iii. Devices prescribed or used for sleep disordered breathing including Continuous Positive Airway Pressure (CPAP), mandibular advancement devices, tongue displacement devices iv. Use of any intranasally administered medications (e.g. Miacalcin) b) Within 3 days prior to the initiation of the baseline qualification phase: i. Oral decongestants ii. Short-acting prescription and non-prescription antihistamines, including ocular preparations and antihistamines contained in OTC sleep medications or ‘night time’ pain formulations (e.g. Benadryl, Chlortrimeton, Dimetane, Tavist) iii. Intranasal, oral or inhaled anticholinergics (e.g. Atrovent) iv. Long-acting beta agonists (e.g. Serevent) v. Oral antileukotrienes c) Within 7 days prior to the initiation of the baseline qualification phase: i. Any topical nasal decongestants (nasal sprays, drops, etc). ii. OTC products such as chin straps, pillows, internal/external nasal dilators. d) Within 10 days prior to initiation of the baseline qualification phase: i. Long-acting antihistamines (e.g. Allegra, Claritin, Clarinex, Zyrtec). e) Within 14 days prior to initiation of the baseline qualification phase: i. Intranasal cromolyn ii. Intranasal antihistamines (e.g. Astelin, Astepro) f) Within 4 weeks prior to the initiation of the baseline qualification phase: i. Intranasal corticosteroids g) Within 8 weeks prior to the initiation of the baseline qualification phase: i. Inhaled oral, intramuscular, intravenous, ocular and/or dermatological corticosteroid (with the exception of 1% or less topical hydrocortisone products) h) Within 3 months prior to the baseline qualification phase: i. Intranasal vaccines.
- Participant has experienced an acute upper respiratory tract infection during the qualification phase and/or at the Baseline visit.
- Participant abuses alcohol (regularly drinks more than 3 drinks per day) or has a recent history (within last 2 years) of substance or alcohol abuse
- Participant has a positive urine drug screening result (dipstick) for drugs of abuse (cannabinoids, opiates, amphetamines, methamphetamine, cocaine, barbiturates, methadone and/or its metabolites, ecstasy).
- Participant has self-reported severe, unstable disease states (e.g. myocardial infarction, congestive heart failure, diabetes, cirrhosis, cancer, epilepsy, or stroke), pain syndromes, (e.g. fibromyalgia) or any medical or surgical condition that places the Participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study or who in the judgement of the principal investigator would not be suitable for entry into this study.
- Severe nasal obstruction caused by structural abnormality that renders the Participant unsuitable for the study in the opinion of the investigator, i.e. significant nasal polyps, severe deviated septum.
- Participant who is pregnant or nursing, by self-report.
- Participation in another clinical study.
- Receipt of an investigational drug within 30 days of the start of the baseline qualification phase.
- Previous participation in this study.
- Personnel: An employee of the sponsor or the study site or members or their immediate family.
Trial location(s)
Location
Radiant Research - Cincinnati
Cincinnati, OH, United States, 45249
Status
Study Complete
Study documents
Statistical analysis plan
Available language(s): English
Protocol
Available language(s): English
Clinical study report
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2011-14-01
Actual study completion date
2011-14-01
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website